RxDoctor Payments Data

Huong Quy, DO

Family Medicine · Westminster, CANPI 1588826150

Payments from drug & device makers

$475in general payments, 2019–2025

Across 15 payments — averaging $31.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$109
  • Dexcom, Inc.$80
  • Covidien LP$74
  • Amarin Pharma, Inc.$65
  • AstraZeneca$42
  • Gilead$31
  • plus $73 from 3 others

What the payments were for

  • Food & beverage$475100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$475 in reported general payments places this provider in the 60th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$177,206
Medicare patients
187
Services billed
1,978

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin142$119,964
JanuviaSitagliptin Phosphate126$88,234
ProliaDenosumab50$82,296
OzempicSemaglutide52$66,727
VascepaIcosapent Ethyl75$51,900
LinzessLinaclotide56$50,499
TradjentaLinagliptin56$46,597
Diclofenac Sodium52$41,698
FarxigaDapagliflozin Propanediol39$35,611
CreonLipase/Protease/Amylase24$34,667
ZenpepLipase/Protease/Amylase17$21,819
Incruse ElliptaUmeclidinium Bromide30$14,765
DapagliflozinDapagliflozin Propanediol21$13,662
Repatha SureclickEvolocumab17$11,550
AlogliptinAlogliptin Benzoate24$9,323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$109$166,561198 claims
AbbVieLinzess, Creon$26$85,16780 claims
AmgenProlia$26$82,29650 claims
Novo NordiskOzempic$20$66,72752 claims
AstraZenecaFarxiga$42$35,61139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 10,533 family medicine providers in California.

Other family medicine in Westminster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →